152 related articles for article (PubMed ID: 35022675)
21. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
22. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
25. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
27. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of clinicopathologic characteristics of gastric cancer patients undergoing gastrectomy based on a single-center gastric cancer database with above 10 000 cases].
Liang WQ; Xi HQ; Qiao S; Cui JX; Zhang KC; Gao YH; Song YN; Zhang L; Luo H; Wei B; Xue WG; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1051-1058. PubMed ID: 33212553
[No Abstract] [Full Text] [Related]
29. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
[TBL] [Abstract][Full Text] [Related]
30. Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective cohort study.
Takechi H; Fujikuni N; Tanabe K; Hattori M; Amano H; Noriyuki T; Nakahara M
BMC Gastroenterol; 2020 Aug; 20(1):256. PubMed ID: 32758144
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
34. A decision analysis comparing three strategies for peritoneal lavage cytology testing in staging of gastric cancer in China.
He Q; Zhu J; Wang A; Ji K; Ji X; Zhang J; Wu X; Li X; Bu Z; Ji J
Cancer Med; 2020 Dec; 9(23):8940-8949. PubMed ID: 33047873
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
36. Robotic-assisted gastrectomy compared with open resection: a comparative study of clinical outcomes and cost-effectiveness analysis.
Caruso R; Vicente E; Núñez-Alfonsel J; Ferri V; Diaz E; Fabra I; Malave L; Duran H; Isernia R; D'Ovidio A; Pinna E; Ielpo B; Quijano Y
J Robot Surg; 2020 Aug; 14(4):627-632. PubMed ID: 31620970
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
McCarthy G; Fenu E; Bennett N; Almond C
Adv Ther; 2019 Mar; 36(3):632-644. PubMed ID: 30726549
[TBL] [Abstract][Full Text] [Related]
38. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
39. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
